BioNTech & DualityBio Start Pivotal Phase 3 Trial for Breast Cancer Drug BNT323/DB-1303
Ticker: BNTX · Form: 6-K · Filed: Jan 22, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: clinical-trial, drug-development, biotechnology, breast-cancer
TL;DR
**BioNTech just started a crucial Phase 3 trial for a new breast cancer drug, BNT323/DB-1303, a big step towards potential market approval.**
AI Summary
BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. announced on January 22, 2024, that the first patient with metastatic breast cancer has been treated in a pivotal Phase 3 trial for their antibody-drug conjugate (ADC) candidate, BNT323/DB-1303. This drug targets the HER2 protein, a common cancer cell surface protein. This matters to investors because a successful Phase 3 trial could lead to market approval and significant revenue, while failure could cause the stock to drop due to the high costs and risks associated with drug development.
Why It Matters
This filing signals a significant step forward in the development of a potential new cancer treatment, which could open up a new revenue stream for BioNTech if successful.
Risk Assessment
Risk Level: medium — While progressing to Phase 3 is positive, clinical trials still carry significant risk of failure, which could negatively impact BioNTech's stock.
Analyst Insight
A smart investor would monitor the progress of the BNT323/DB-1303 Phase 3 trial closely, as successful outcomes could significantly de-risk the investment and drive future growth for BioNTech.
Key Players & Entities
- BioNTech SE (company) — registrant and co-developer of BNT323/DB-1303
- Duality Biologics (Suzhou) Co., Ltd. (company) — co-developer of BNT323/DB-1303
- BNT323/DB-1303 (drug) — next-generation antibody-drug conjugate (ADC) candidate
- Dr. Sierk Poetting (person) — Chief Operating Officer of BioNTech SE, signed the report
- January 22, 2024 (date) — date of announcement and filing, and date first patient treated
- HER2 (protein) — Human Epidermal Growth Factor Receptor 2, targeted by BNT323/DB-1303
Forward-Looking Statements
- Successful completion of the Phase 3 trial for BNT323/DB-1303 could significantly boost BioNTech's stock price. (BioNTech SE) — medium confidence, target: 2026-2028 (typical Phase 3 duration)
- Failure of the BNT323/DB-1303 Phase 3 trial would likely lead to a notable decline in BioNTech's share value. (BioNTech SE) — medium confidence, target: 2026-2028
FAQ
What is the specific drug candidate mentioned in the filing?
The specific drug candidate is BNT323/DB-1303, which is described as a next-generation antibody-drug conjugate (ADC) targeting the Human Epidermal Growth Factor Receptor 2 (HER2).
Which companies are collaborating on this drug candidate?
BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. are collaborating on the drug candidate BNT323/DB-1303.
What type of cancer is the Phase 3 trial targeting?
The Phase 3 trial is evaluating the efficacy and safety of BNT323/DB-1303 in patients with metastatic breast cancer.
When was the announcement made regarding the initiation of the Phase 3 trial?
The announcement was made on January 22, 2024, stating that the first patient had been treated in the pivotal Phase 3 trial.
Who signed the 6-K report on behalf of BioNTech SE?
Dr. Sierk Poetting, the Chief Operating Officer of BioNTech SE, signed the 6-K report on January 22, 2024.
Filing Stats: 273 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2024-01-22 09:14:33
Filing Documents
- form6-kbnt323dbx1303fpdpha.htm (6-K) — 13KB
- a99_1240122xbnt323xdb-1303.htm (EX-99.1) — 30KB
- image_0a.jpg (GRAPHIC) — 42KB
- image_1a.jpg (GRAPHIC) — 7KB
- 0001776985-24-000004.txt ( ) — 112KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JANUARY 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On January 22, 2024, BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. announced that the first patient with metastatic breast cancer has been treated in a pivotal Phase 3 trial evaluating the efficacy and safety of the next-generation antibody-drug conjugate ("ADC") candidate BNT323DB-1303 targeting the Human Epidermal Growth Factor Receptor 2 ("HER2"), a cancer cell surface protein. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Dr. Sierk Poetting Name Dr. Sierk Poetting Title Chief Operating Officer Date January 22, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323DB-1303 in Metastatic Breast Cancer